Stemedica Cell Technologies, Inc. Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells

SAN DIEGO, Sept. 1 /PRNewswire/ -- Stemedica Cell Technologies, Inc., ("Stemedica"), a leader in adult stem cell research and manufacturing, announced today that it has been granted a license by the State of California's Food & Drug Branch to manufacture stem cells for human clinical trials. This Drug Manufacturing License recognizes Stemedica as being compliant with California law and the applicable provisions of the Code of Federal Regulations.

"This stamp of approval positions Stemedica as one of only a few companies in the world capable of manufacturing and delivering its own unique multiple cell products and factors. The Company also has the ability to custom manufacture for select companies. These dynamic capabilities give us a significant point of advantage in the marketplace," said Roger Howe, PhD, Executive Chairman for Stemedica.

"We're very proud of the hard work, dedication and professionalism of the team that has made this possible," stated Maynard Howe, PhD, Stemedica's Vice Chairman and Chief Executive Officer. "Their experience and expertise has been instrumental in assuring that our facility meets regulatory compliance requirements. With the approval and licensing process behind us we can now focus our efforts on manufacturing the highest quality stem cell products."

Media Contact for Stemedica: Dave McGuigan at dmcguigan (at) stemedica.com

Stemedica Cell Technologies, Inc.